VANCOUVER, British Columbia, December 17, 2025--(BUSINESS WIRE)--iGMS, an award-winning short-term rental platform and official Airbnb Partner, today announced the launch of their most advanced ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

DALLAS, Oct. 9, 2025 /PRNewswire/ -- Birdseye Security Solutions, a North American Leader in AI-driven Remote Facility Supervision in trucking and logistics, is proud to announce the official launch ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of IGM Biosciences, Inc. (NASDAQ: IGMS) to Concentra Biosciences, LLC is fair to IGM ...

Ayyoun is a staff writer who loves all things gaming and tech. His journey into the realm of gaming began with a PlayStation 1 but he chose PC as his platform of choice. With over 6 years of ...

The tutorial of Elden Ring Nightreign has players fighting the Fell Omen. Many will fall to this boss, unable to beat it. But that begs the question: What do you get if you beat the Fell Omen in the ...

In this video, I walk you through everything you need to know to start using Microsoft Word. Whether you're brand new or just need a quick refresher, I show you how to open the program, start a new ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...